Back to rankings

Encompass Health Corp (EHC)

Fair Value
HealthcareMedical Care FacilitiesUnited States

Fundamental

67

Price

$121.49

Market Cap

$12.23B

Part 1 · What the company is worth

Overview

Encompass Health is the largest owner and operator of inpatient rehabilitation hospitals in the United States. Its hospitals take patients who have just come through an acute-care stay — after a stroke, a hip fracture, major surgery, a brain or spinal cord injury, or a debilitating neurological illness — and give them intensive, physician-supervised rehabilitation for a stay typically measured in days to a few weeks, with the goal of sending them home rather than to a nursing facility. As of December 31, 2025 the company operated 173 inpatient rehabilitation hospitals in 39 states and Puerto Rico, with 11,465 licensed beds, and recorded 263,299 discharges during the year. Some hospitals are wholly owned; others are joint ventures with local acute-care hospital systems, which also supply patient referrals. Since the July 2022 spin-off of its home health and hospice business (Enhabit), inpatient rehabilitation is the only business the company runs.

How it makes money

Revenue is a per-patient, per-stay payment collected almost entirely from third-party payors rather than from patients. Traditional Medicare, which pays inpatient rehabilitation facilities a prospective lump sum per discharge based on the patient's condition and case mix rather than on days or services used, is by far the largest source. Growth comes from filling existing beds, adding beds to current hospitals, and opening or acquiring new ones. Of $5,935.2 million of net operating revenues in fiscal 2025, $5,756 million came from inpatient services and roughly $179 million from other sources. The 2025 payor mix was 65.4% traditional Medicare, 16.4% Medicare Advantage, 10.7% managed care, 3.1% Medicaid, 0.7% other third-party payors, 0.5% workers' compensation, 0.3% paid directly by patients, and 2.9% other income.

Competitive moat

Scale · Narrow

Encompass Health is the largest operator in its niche, with 173 hospitals and 11,465 licensed beds at the end of 2025, and that scale is real: a national footprint spreads clinical protocols, staffing systems and the cost of regulatory compliance across far more discharges than a single-hospital competitor can. Barriers are reinforced by the rules themselves — an inpatient rehabilitation facility must meet strict Medicare admission criteria and quality-reporting obligations, and in many states a new hospital needs a certificate of need. Referral relationships with acute-care hospitals, several of them formalised as joint ventures with the referring system, are sticky for the same reason. But the advantage is narrow, not wide: the company's own filing lists competitive pressure among its risk factors, patients can be sent instead to skilled nursing facilities or home health, and the dominant payor sets the price unilaterally, so scale protects cost per discharge more than it protects the revenue line.

What drives demand

Defensive

Nobody schedules a stroke around the business cycle. Demand comes from the incidence of disabling medical events — strokes, hip fractures, major surgeries, neurological disease — in an ageing population, and from acute-care hospitals wanting to discharge patients who still need intensive care. That makes volumes largely independent of recessions and consumer confidence: discharges rose in each of the last three years while revenue went from $4,801.2 million in 2023 to $5,373.2 million in 2024 and $5,935.2 million in 2025. The cyclical exposure that exists is political and fiscal rather than economic: the Medicare payment rate, the Medicare Advantage share of patients, and the wage cost of clinical staff.

Key risks

  • Cuts, delays or suspension of reimbursement — The filing lists reductions or delays in, or suspension of, reimbursement by governmental or private payors as its first risk factor. Medicare sets the price administratively, so a rule change made in Washington reaches revenue without any commercial negotiation.
  • Restrictive reading of what Medicare will pay for, and claim audits — Two separate risk factors cover restrictive interpretations of the regulations governing reimbursable claims and audits that may assert the company was overpaid. A further factor flags substantive and procedural deficiencies in the administrative appeals process for denied Medicare claims — money already earned can be clawed back and contested slowly.
  • Shift in payor mix or patient acuity — The company states that changes in its payor mix or in the acuity of its patients could reduce revenues or profitability. Medicare Advantage plans and third-party payors and 'conveners' working to steer patients and cut payments to providers are called out as a distinct risk.
  • Hiring and keeping clinical staff — Among operational risks the filing names the inability to attract and retain nurses, therapists and other healthcare professionals. Staffing is the input the business cannot substitute: beds without clinicians cannot take patients.
  • Referral sources and joint-venture partners — Risk factors cover the inability to maintain or develop relationships with patient referral sources, and the possibility that acute-care hospitals participating in joint ventures with the company experience operational or financial difficulties of their own.
  • Regulation, licensing and compliance — The company flags changes in healthcare rules at federal, state or local level, compliance with extensive and frequently changing laws applicable to healthcare providers, the inability to maintain proper licensing, quality-reporting requirements, and adverse outcomes of lawsuits and regulatory proceedings including qui tam suits.
  • Expansion that does not integrate, and information-system incidents — The filing lists the inability to complete and integrate de novo developments, acquisitions, investments and joint ventures, and separately incidents affecting the operation, availability or security of the company's or its vendors' information systems, including patient information held in them.
  • Debt and its covenants — Under financial risks the company states that its debt and the associated restrictive covenants could have negative consequences, alongside general conditions in the economy and capital markets, and warns it may be unable or unwilling to continue declaring and paying dividends.

Customer concentration

Top customers account for 65.4% of revenue

The real customer here is a payor, not a patient. Traditional Medicare alone accounted for 65.4% of 2025 revenues; Medicare Advantage plans added 16.4% and managed care 10.7%, with Medicaid at 3.1% and everything else in small single digits. The filing states plainly that revenues and receivables from Medicare are significant to its operations. Concentration of this kind is normal for an inpatient rehabilitation operator, but it means one administrative decision by a single payer moves the majority of the revenue line, and the company has no pricing power over it.

The case for

Buyers argue that this is the leading operator in a niche whose demand is set by demographics rather than by the economy, and that the company is still adding capacity into it: 173 hospitals at the end of 2025 against 166 a year earlier, with revenue up from $5,373.2 million to $5,935.2 million. They point to the position as the largest inpatient rehabilitation operator, to joint ventures that tie the company to the acute-care hospitals sending it patients, and to regulatory requirements — Medicare admission criteria, certificate-of-need rules in many states — that make a new competing hospital slow to build. They also argue the business is simpler to follow since the 2022 Enhabit spin-off left a single line of business.

The case against

Sellers fear a business whose price is set by the government. Traditional Medicare paid 65.4% of 2025 revenues and Medicare Advantage another 16.4%, and the company's own risk factors open with reductions, delays or suspension of reimbursement, restrictive readings of which claims are payable, audits asserting overpayment, and appeals processes it describes as procedurally deficient. They point to the risk factor on payor mix: as patients move from traditional Medicare toward Medicare Advantage plans and third-party 'conveners' that work to steer patients and cut payments, the same discharge can earn less. They add the staffing risk the company discloses — nurses and therapists it may not be able to attract or retain — the cost of growing by building and acquiring hospitals that must then be integrated, and debt with restrictive covenants in a business that cannot raise its own prices to cover a squeeze.

Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users

Direct competitors

Who this company fights with for the same customers

Compare

Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users

P/E: 14.7Score: 76Market cap: $95.97B

As the largest hospital-based provider of inpatient rehabilitation in the country, HCA keeps inside its own rehabilitation units the patients that Encompass Health names as its primary source of admissions.

Select Medical Holdings CorporationSEM

It is the only other large listed operator of freestanding inpatient rehabilitation hospitals, competing for the same post-surgical and post-stroke patients referred out of acute-care hospitals in overlapping US markets.

Lifepoint Rehabilitation (Lifepoint Health, Inc.)Not tracked

Privately held Lifepoint runs more than 45 joint-venture rehabilitation hospitals with regional health systems, competing with Encompass Health for exactly those hospital partnerships and the patients they feed.

Ernest Health, Inc.Not tracked

A private operator of 45 rehabilitation hospitals across 14 states, it competes bed-for-bed with Encompass Health in Western and Southern markets such as Texas, Arizona and New Mexico.

PAM Health (Post Acute Medical, LLC)Not tracked

This private post-acute group runs inpatient rehabilitation hospitals alongside long-term acute care facilities in over twenty states, taking the same Medicare rehabilitation admissions in the markets where the two overlap.

Balance Sheet & Liquidity

Revenue

$6.21B

Trailing 12 months (through 6/30/2026)

Net Income

$621M

Trailing 12 months (through 6/30/2026)

Free Cash Flow

$439M

Total Equity

$2.44B

Total Liabilities

$3.81B

Current Ratio

1.19

Interest Coverage

-

Debt/EBITDA

1.94

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseFairly Valued

Fair Value

$138.97

Current Price

$121.49

Margin of Safety

+12.6%

Fair Value Range

$113.52 - $164.42

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$148.17
Discounted cash flow (DCF):$148.92
Earnings multiple (P/E):$112.88
Graham growth formula:$194.93
Earnings power value (EPV):$94.66
Justified P/B:$96.81
Dividend discount (Gordon):$13.92
P/FFO, funds from operations:$145.01
Mid-cycle earnings:$172.64
Revenue multiple:$244.51
Analyst Consensus:Strong Buy (17B / 1H / 0S)
Last Earnings Surprise:+3.72%

Valuation Metrics

P/E Ratio

19.79

ROE

23.2%

P/B Ratio

4.61

P/FCF

28.99

Gross Margin

-

ROIC

-

Profitability Radar

Value Creation (Economic Moat)

ROIC

-

WACC

8.2%

ROIC − WACC

-

Fundamental Analysis Criteria

Passed (17)

  • EPS shows upward trend
  • Price CAGR 14.01%
  • P/FCF 28.99
  • Debt/Equity ratio
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 25.0%
  • Revenue Growth 5Y 10.7%
  • Analyst Consensus 94% Buy
  • Earnings Surprise avg 5.7%
  • PEG Ratio 1.39
  • Earnings Quality (OCF/NI) 1.95
  • Share Dilution 0.0%
  • Net Margin Trend 10.0% vs 9.2%
  • Piotroski F-Score 8/9

Failed (6)

  • EPS CAGR 4.50%
  • P/B Ratio 4.61
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)

Unavailable (5)

  • ROIC NaN%
  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage

Piotroski F-Score

8/9

Strong financial health

score
criteria

Earnings Quality

1.95

High quality: earnings backed by cash

Share Dilution

0.0%

Buying back shares. Shareholder friendly

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Mark J. TarrCEO, President & Director63
Mr. Douglas E. ColtharpExecutive VP & CFO63
Mr. Patrick W. TuerExecutive VP & COO40
Mr. John Patrick DarbyExecutive VP, General Counsel & Corporate Secretary60
Dr. Elissa Joy Charbonneau D.O., M.S.Chief Medical Officer65
Mr. Andrew L. PriceSenior VP & Chief Accounting Officer58
Mr. Rusty YeagerChief Information Officer & Senior VP-
Mr. Mark MillerSenior Vice President of Investor Relations & Strategic Planning-
Ms. Dawn RockChief Compliance Officer-
Mr. Anthony A. HernandezChief Human Resources Officer59

Audit Risk

1

Board Risk

2

Compensation Risk

2

Shareholder Rights Risk

2

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-26

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-08-07

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-08-13

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Latest News

Recent headlines for EHC, sourced from Markets Gazette.

No recent news for EHC.